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Case Report
Transvenous Valve-in-Valve Replacement Preserving
the Function of a Transvalvular Defibrillator Lead
Pieter De Meester,1 MD, Werner Budts,1 MD, PhD, and Marc Gewillig,2* MD, PhD
Although feasibility and efficacy of percutaneous tricuspid valve-in-valve implantation
have been established, a transtricuspid pacing or defibrillator lead might preclude this
technique: lead damage can cause lead dysfunction resulting in inappropriate or ineffi-
cient pacing or shocks. In these cases, lead removal is thought to be the only option.
We describe a patient who presented with rapid clinical deterioration due to tricuspid
valve stenosis early after implantation of an internal defibrillator with a transvalvular
shock-lead. A transvenous valve-in-valve implantation of the tricuspid valve was per-
formed after protecting the defibrillator-lead with a custom-made covered stent. We
describe the technical issues, the clinical outcome, and the evolution of lead function
after implantation. VC 2014 Wiley Periodicals, Inc.
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INTRODUCTION
In patients at high risk for cardiac surgery, feasibility
and efficacy of percutaneous tricuspid valve-in-valve
implantation have been established [1–3]. However,
patients with a transtricuspid pacing or defibrillator
lead challenge the interventional cardiologist with a di-
lemma: the valved stent can damage the lead causing
dysfunction, inadequate sensing or pacing, which in
turn may result in delivering inappropriate or ineffi-
cient shocks [4,5].
We describe a patient who presented with sympto-
matic tricuspid valve stenosis after implantation of a
transvalvular shock-lead. A transvenous valve-in-valve
implantation of the tricuspid valve was performed after
protecting the defibrillator lead with a covered stent.
CASE REPORT
A 42-year-old male presented for percutaneous reval-
vulation of the tricuspid valve. He was born with an arte-
rial trunc, underwent pulmonary artery banding in
infancy, and was repaired at the age of five. Later, multi-
ple re-interventions were needed. At the age of 29 years,
right ventricular outflow tract reconstruction with a
Carpentier-Edwards size 27 mm bioprosthesis, as well as
implantation of a tricuspid valve Carpentier-Edwards size
33 mm bioprosthesis was performed. Symptomatic runs
of ventricular tachycardia at the age of 40 years were
treated with an internal defibrillator (ICD) Medtronic Vir-
tuosoVR VR connected to a 9 Fr transvalvular shock lead
(Medtronic 6947).
In the years following ICD implantation, tricuspid
valve stenosis developed with rapid clinical deterioration
in 2 years. He presented now in NYHA functional class
IV with severe right heart failure and anasarc edema.
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